Non-insulin Therapies for Diabetes Market Size is Expected to Rise at a CAGR of 5.8% by 2034: TMR Research

Diabetes mellitus is a chronic condition characterized by elevated blood glucose levels due to the body's inability to produce or effectively use insulin. While insulin therapy has been a cornerstone in diabetes management, there is a growing demand for non-insulin therapies that offer effective glucose control with fewer side effects and improved patient compliance. The global market for non-insulin therapies for diabetes is expanding, driven by advancements in drug development, increasing prevalence of diabetes, and a shift towards personalized medicine. This article explores the current state and future prospects of the non-insulin therapies market.

Non-insulin Therapies for Diabetes Market (당뇨병 시장을 위한 비인슐린 치료법) is expected to grow at a CAGR of 5.8% from 2024 to 2034 and reach US$ 58.6 Bn by the end of 2034

Download Sample of the Report:
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86328

Overview of Non-insulin Therapies for Diabetes Market
The global non-insulin therapies market is witnessing significant growth, driven by the rising prevalence of diabetes, technological advancements in drug development, and increasing patient preference for non-invasive treatments. The market is segmented by drug class (GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors, alpha-glucosidase inhibitors, amylin analogs, and others), route of administration (oral, injectable), end-users (hospitals, clinics, home care settings), and geographical regions.

Top Companies:

GSK plc
Eli Lilly and Company
Sumitomo Pharma
Intarcia Therapeutics
Servier Laboratories
Pfizer Inc.
Merck & Co., Inc.
Dong-A Pharmaceutical Co., Ltd.
Luye Pharma Group
Eurofarma Laboratories SA

Recent Developments in Non-insulin Therapies Market
Recent advancements and trends in the non-insulin therapies market include:

Innovative Drug Classes: Development of novel drug classes such as GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors that offer improved glycemic control and additional benefits like weight loss and cardiovascular protection.
Fixed-dose Combinations: Introduction of fixed-dose combination therapies that combine multiple mechanisms of action in a single pill, simplifying treatment regimens and improving adherence.
Extended-release Formulations: Development of extended-release formulations that reduce dosing frequency, enhance patient compliance, and provide more consistent glycemic control.
Digital Health Integration: Integration of digital health technologies, such as mobile apps and wearable devices, to monitor glucose levels, track medication adherence, and provide personalized feedback.
Biosimilars and Generics: Increasing availability of biosimilars and generic versions of non-insulin therapies, making these treatments more affordable and accessible.

Drivers of Market Growth
Several factors contribute to the growth of the non-insulin therapies market:

Rising Diabetes Prevalence: Increasing global prevalence of diabetes, driven by aging populations, rising obesity rates, and sedentary lifestyles, necessitates effective management options.
Patient Preference: Growing patient preference for non-insulin therapies due to their non-invasive nature, fewer side effects, and additional health benefits.
Technological Advancements: Continuous advancements in drug development technologies, leading to the creation of more effective and safer non-insulin therapies.
Healthcare Policies: Favorable healthcare policies and government initiatives aimed at improving diabetes management and patient outcomes.
Focus on Personalized Medicine: Increasing focus on personalized medicine, which tailors treatment plans based on individual patient profiles, enhancing the efficacy of non-insulin therapies.

Explore Sample of the Report:
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86328

Market Segmentation:

Drug Class
Biguanides
Sulfonylureas
Thiazolidinediones
Alpha-Glucosidase Inhibitors
DPP-4 Inhibitors
GLP-1 Analogs
Sodium-glucose co-transporter-2 (SGLT2) Inhibitors

Route of Administration
Oral
Intramuscular

End-user
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Region
North America
Europe
Asia Pacific
Latin America
Middle East & Africa

Buy this Premium Research Report:
https://www.transparencymarketresearch.com/checkout.php?rep_id=86328<ype=S

More Trending Report by Transparency Market Research:

Pharmaceutical Chemicals Market (医薬品化学品市場): https://www.globenewswire.com/en/news-release/2024/01/15/2808957/32656/en/Pharmaceutical-Chemicals-Market-Size-to-be-Worth-USD-339-3-billion-by-2031-with-a-Projected-CAGR-of-5-8-Says-Transparency-Market-Research-Inc.html

OPGW Cable Market (Marché des câbles OPGW): https://www.globenewswire.com/news-release/2024/02/28/2837197/32656/en/OPGW-Cable-Market-Expected-to-Reach-USD-876-8-million-by-2031-Growing-at-a-CAGR-of-4-8-Transparency-Market-Research-Inc.html

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

This release was published on openPR.